Dexcom (DXCM) news
Recent news
Landmark Dexcom Connect study published in the New England Journal of Medicine, redefining the standard of care for people with type 2 diabetes not on insulin
A landmark clinical trial, the Dexcom CONNECT study, has demonstrated that the use of Dexcom G7 continuous glucose monitoring (CGM) systems leads to a clinically and statistically significant reduction in A1C levels and improvement in glucose control among individuals with type 2 diabetes who are…
AInvest Wire · 1d agoDexcom schedules third quarter 2026 earnings release and conference call for October 29, 2026 at 4:30 p.m. Eastern time
AInvest Wire · Oct 7, 2026DEXCOM Inc: RBC raises target price to $105 from $90
RBC Capital has revised its price target for DexCom, Inc. (NASDAQ:DXCM), raising it from $90 to $105, while maintaining an "Outperform" rating for the stock. This adjustment follows DexCom's recent third-quarter earnings report, which exceeded analyst expectations in both earnings per share and…
AInvest Wire · Oct 1, 2026Dexcom Inc: Truist Securities raises target price to $102 from $93
Truist Securities has revised its price target for DexCom Inc (NASDAQ: DXCM) to $102 from $93, reflecting increased outlook for stock . The adjustment indicates the firm’s confidence in DexCom’s growth trajectory and operational momentum. DexCom, a leading provider of continuous glucose monitoring…
AInvest Wire · Sep 18, 2026Dexcom promotes Jereme Sylvain to chief operating officer
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.